Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers (DIDAXI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00691353|
Recruitment Status : Completed
First Posted : June 5, 2008
Last Update Posted : December 3, 2008
Cross - Sectional study requiring one visit at the investigators office for the data collection.
- Target Group: Patients that suffer from Bipolar Disorder Type 1.
- YMRS - HAMILTON and GAF scales are going to be used to assess the clinical outcome. The findings are going to be based on the different scores reported by Specialists (before the patients started to use as a therapy atypical antipsychotics / at the time that the visit actually takes place for the cause of the study.) We predefine the time period that the patient should be using atypical antipsychotics at minimum (2 months).
- The first 9 consecutive patients that visit the Specialist and meet the entry criteria and signs the ICF will be recruited in the study.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||540 participants|
|Official Title:||Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||July 2008|
- Difference in the scores reported in YMRS and Hamilton - D scales from baseline(start of therapy) [ Time Frame: Assessment of the progress of disease 2 to 4 months after the initiation of the therapy(baseline) ]
- Assessment of functioning - Relative score reported in GAF scale [ Time Frame: 2 - 4 months after the initiation of the therapy. No baseline comparison ]
- To depict sociodemographic characteristics and comorbidities. [ Time Frame: Reported at the site visit ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00691353
|Principal Investigator:||Charalambos Touloumis, MD||Athens Psychiatric Hospital Greece|